Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Blazesbon Jun 10, 2020 12:40am
203 Views
Post# 31131836

RE:RE:RE:RE:RE:RE:RE:People's Poll - Adjusting for Risk - Market Price June 10

RE:RE:RE:RE:RE:RE:RE:People's Poll - Adjusting for Risk - Market Price June 10
whc wrote: You're right, big pharma won't buy just anything but this is for pain management.  When people are in pain they are going to buy your product, recession or not.  Big pharma makes billions every year and spend billions in research that often fail.  And here we have a drug that's just been derisked and Dan can't get a bidding war going?


Now Dan doesn't have to 'get a bidding war going'.  Antibe cannot now be compelled to accept a lowball offer--the wolf will not be at the door. 

In that context the cash raise was a good move.  Presumably Wallace and the team are beavering away in the lab with all the time in the world that 25 million will buy.

Meanwhile we retail schmos have to see the proctologist tomorrow to have our short term wishes and dreams extracted from the place management shoved them.
Bullboard Posts